Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

CompletedOBSERVATIONAL

Enrollment

1,927

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

AnemiaNeoplasms

Interventions

DRUG

Epoetin alfa

40,000 IU once weekly, variable treatment length

All Listed Sponsors

lead

Janssen-Cilag B.V.

INDUSTRY

NCT00398749 - Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2) | Biotech Hunter | Biotech Hunter